368 related articles for article (PubMed ID: 17876042)
1. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
4. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
5. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
6. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα.
Gui M; Shi DK; Huang M; Zhao Y; Sun QM; Zhang J; Chen Q; Feng JM; Liu CH; Li M; Li YX; Geng M; Ding J
Invest New Drugs; 2011 Oct; 29(5):800-10. PubMed ID: 20336347
[TBL] [Abstract][Full Text] [Related]
7. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
Bau JT; Kang Z; Austin CA; Kurz EU
Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
[TBL] [Abstract][Full Text] [Related]
8. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
[TBL] [Abstract][Full Text] [Related]
9. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
11. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
12. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
14. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
15. Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Park S; Kadayat TM; Jun KY; Thapa Magar TB; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Jan; 125():14-28. PubMed ID: 27643560
[TBL] [Abstract][Full Text] [Related]
16. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
17. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
18. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
Bau JT; Kurz EU
Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
